Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 74.73 USD | -0.92% | -0.24% | -12.84% | |
| Sep. 28 | GSK lifts growth ambitions for HIV business on long-acting drug | RE |
| Sep. 19 | Gilead Sciences Gets EU Committee's Positive Opinion on Expanding Veklury's Indication | MT |
Financials (USD)
| Sales 2023 * | 26,872 M | Sales 2024 * | 27,519 M | Capitalization | 93 974 M |
|---|---|---|---|---|---|
| Net income 2023 * | 5,763 M | Net income 2024 * | 6,621 M | EV / Sales 2023 * | 4,02x |
| Net Debt 2023 * | 14,092 M | Net Debt 2024 * | 9,430 M | EV / Sales 2024 * | 3,76x |
| P/E ratio 2023 * | 16,3x | P/E ratio 2024 * | 14,0x | Employees | - |
| Yield 2023 * | 4,06% | Yield 2024 * | 4,24% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.17% | ||
| 1 week | +0.20% | ||
| Current month | -1.39% | ||
| 1 month | -2.10% | ||
| 3 months | -1.00% | ||
| 6 months | -6.85% | ||
| Current year | -12.15% |
1 week
74.53
76.27
1 month
73.2578.50
Current year
73.2588.29
1 year
61.4589.74
3 years
56.5689.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 53 | 2019 |
Merdad Parsey
CTO | Chief Tech/Sci/R&D Officer | 60 | 2019 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Javier Rodriguez
BRD | Director/Board Member | 52 | 2020 |
Daniel O'Day
CHM | Chairman | 58 | 2019 |
Kevin Lofton
BRD | Director/Board Member | 68 | 2009 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 189 M$ | -5.94% | - | |
| 3.55% | 2 M$ | -0.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-29 | 74.83 | -0.78% | 1 501 887 |
| 23-09-28 | 75.42 | -0.17% | 3,483,111 |
| 23-09-27 | 75.55 | +0.03% | 4,442,649 |
| 23-09-26 | 75.53 | +0.94% | 5,643,933 |
| 23-09-25 | 74.83 | -0.24% | 3,885,751 |
Delayed Quote Nasdaq, September 28, 2023 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
Sector
Pharmaceuticals
Calendar
2023-10-25
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.42USD
Average target price
91.36USD
Spread / Average Target
+21.14%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -12.15% | 93 974 M $ | |
| +3.92% | 73 893 M $ | |
| -19.19% | 121 B $ | |
| +0.97% | 63 659 M $ | |
| +12.15% | 133 B $ | |
| -4.02% | 53 776 M $ | |
| +36.73% | 50 860 M $ | |
| +12.62% | 48 629 M $ | |
| -6.16% | 47 076 M $ | |
| +3.11% | 145 B $ |
